Cigna®

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

Faslodex
(fulvestrant)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		

Urgency:
☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

Medication Requested:
☐ Faslodex 250mg/5mL syringe ICD10:

Dose: Frequency of therapy: Duration of therapy:

Where will this medication be obtained?
☐ Accredo Specialty Pharmacy**
☐ Prescriber's office stock (billing on a medical claim form)
☐ Other (please specify):
☐ Retail pharmacy
☐ Home Health / Home Infusion vendor
***Cigna's nationally preferred specialty pharmacy*

*****Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 | NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557*

Facility and/or doctor dispensing and administering medication:
Facility Name: State: Tax ID#:
Address (City, State, Zip Code):

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No

Diagnosis related to use?
☐ breast cancer
☐ endometrial cancer
☐ ovarian carcinoma
☐ uterine sarcoma
☐ other (please specify):

Clinical Information
(if breast cancer) What is your patient's HER2 (human epidermal growth factor receptor 2) status?
☐ HER2-positive (HER2+, HER2 gene amplification, or HER2 protein overexpression)
☐ HER2-negative (HER2- or no HER2 gene amplification)
☐ unknown

(if HER2-negative breast cancer) Does your patient have hormone receptor (HR)-positive disease? Yes ☐ No ☐
(if HER2-negative breast cancer) Does your patient have locally advanced or metastatic disease? Yes ☐ No ☐
(if HER2-negative breast cancer) Is your patient postmenopausal? Yes ☐ No ☐
(if no) Is your patient male? Yes ☐ No ☐
(if male) Is your patient also on an aromatase inhibitor (like anastrozole, Arimidex, Aromasin, exemestane, Femara, or letrozole)? Yes ☐ No ☐
(if yes) Will there be concomitant suppression of testicular steroidogenesis? Yes ☐ No ☐

(if HER2-positive breast cancer) How will the requested medication be used?
☐ As a single agent
☐ In combination with trastuzumab
☐ Other/Unknown

(if ovarian) Does your patient have recurrent disease? Yes ☐ No ☐
(if ovarian) Is your patient's tumor considered "low-grade" (grade 1)? Yes ☐ No ☐

(if ovarian) What type of ovarian carcinoma does the patient have?
☐ clear cell
☐ endometrioid
☐ mixed tumors
☐ mucinous
☐ serous
☐ other/unknown:

Additional pertinent information *(please include disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently*):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature:_____ **Date:**_____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v010124